In Brief: Ciba Vision/Autonomous Technologies Corp.
This article was originally published in The Gray Sheet
Ciba Vision/Autonomous Technologies Corp.: Ciba Vision makes a second investment of an undisclosed amount in Orlando, Florida-based Autonomous, which is developing the T-PRK tracker-assisted photorefractive keratectomy laser instrument. Ciba gained "certain marketing rights" to the T-PRK when it made an initial investment last year ("The Gray Sheet" June 20, 1994, In Brief). The new investment marks a "worldwide, two-way exclusive strategic alliance for the co-promotion" of the T-PRK, Ciba says. Autonomous has completed a 25-patient study of the system in Greece; enrollment has started on a 125-patient trial in Greece, with data expected in the fall. Autonomous says it is in discussions with FDA regarding submission of an investigational device exemption for U.S. clinicals of the device...
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.